Two days after it issued its April 25 report on CME, the United States Senate Committee on Finance followed up with a letter to the Accreditation Council for CME, highlighting its concerns that the ACCME’s oversight is insufficient to guarantee that programs are independent of drug company influence. The ACCME'’s review process does not necessarily detect whether providers are catering to commercial supporters by favorably presenting their drugs in activities -- and if providers are ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to Uncle Sam Puts the Squeeze on ACCME, you'll get exclusive access to a large archive of premium content.

Already registered? here.